Alector, Inc. reiterated earnings guidance for the year ending 2023. For the year, company continues to anticipate collaboration revenue to be between $90 and $100 million, total research and development to be between $210 million and $220 million and total general and administrative expenses to be between $60 million and $65 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.775 USD | -5.07% | -6.92% | -40.16% |
May. 14 | Transcript : Alector, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:55 AM | |
May. 08 | Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.16% | 460M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.98% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ALEC Stock
- News Alector, Inc.
- Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023